---
figid: PMC5418169__40169_2017_147_Fig1_HTML
figlink: /pmc/articles/PMC5418169/figure/Fig1/
number: Fig.Â 1
caption: Negative feedback regulates the RAS/MAPK pathway. Although MAPK signaling
  was previously considered linear, autoregulatory negative feedback loops precisely
  control signaling output. MEK inhibitors reduce activity of ERK1 and ERK2 and then
  relieve the feedback inhibition of RAF, resulting in enhancement of RAF kinase activity.
  Likewise, ETS1-targeted therapy may activate ERK1 and ERK2 by inhibiting DUSP6,
  which is an ETS1 transcriptional target
pmcid: PMC5418169
papertitle: 'ETS-targeted therapy: can it substitute for MEK inhibitors?.'
reftext: Osamu Tetsu, et al. Clin Transl Med. 2017;6:16.
pmc_ranked_result_index: '68019'
pathway_score: 0.9457617
filename: 40169_2017_147_Fig1_HTML.jpg
figtitle: Negative feedback regulates the RAS/MAPK pathway
year: '2017'
organisms: Homo sapiens
ndex: 7bfcbd1a-deb1-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5418169__40169_2017_147_Fig1_HTML.html
  '@type': Dataset
  description: Negative feedback regulates the RAS/MAPK pathway. Although MAPK signaling
    was previously considered linear, autoregulatory negative feedback loops precisely
    control signaling output. MEK inhibitors reduce activity of ERK1 and ERK2 and
    then relieve the feedback inhibition of RAF, resulting in enhancement of RAF kinase
    activity. Likewise, ETS1-targeted therapy may activate ERK1 and ERK2 by inhibiting
    DUSP6, which is an ETS1 transcriptional target
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - DUSP6
  - SOS2
  - SOS1
  - HRAS
  - KRAS
  - NRAS
  - MAPK3
  - ETS1
  - MAP2K1
  - MAP2K2
  - RAF1
  - MAPK1
  - ARAF
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: DUSP6
  symbol: DUSP6
  source: hgnc_symbol
  hgnc_symbol: DUSP6
  entrez: '1848'
- word: Sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: Sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ETS1
  symbol: ETS1
  source: hgnc_symbol
  hgnc_symbol: ETS1
  entrez: '2113'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
